Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy
- PMID: 38413478
- DOI: 10.1007/s11010-024-04933-1
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy
Abstract
Cancer remains a major global health concern with high mortality rates mainly due to late diagnosis and poor prognosis. Long non-coding RNAs (lncRNAs) are emerging as key regulators of gene expression in human cancer, functioning through various mechanisms including as competing endogenous RNAs (ceRNAs) and indirectly regulating miRNA expression. LncRNAs have been found to have both oncogenic and tumor-suppressive roles in cancer, with the former promoting cancer cell proliferation, migration, invasion, and poor prognosis. Recent research has shown that lncRNAs are expressed in various immune cells and are involved in cancer cell immune escape and the modulation of the tumor microenvironment, thus highlighting their potential as targets for cancer immunotherapy. Targeting lncRNAs in cancer or immune cells could enhance the anti-tumor immune response and improve cancer immunotherapy outcomes. However, further research is required to fully understand the functional roles of lncRNAs in cancer and the immune system and their potential as targets for cancer immunotherapy. This review offers a comprehensive examination of the multifaceted roles of lncRNAs in human cancers, with a focus on their potential as targets for cancer immunotherapy. By exploring the intricate mechanisms underlying lncRNA-mediated regulation of cancer cell proliferation, invasion, and immune evasion, we provide insights into the diverse therapeutic applications of these molecules.
Keywords: Cancer; Cancer immunotherapy; Gene expression; LncRNA regulation; Long non-coding RNA; Treatment strategies.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.Front Immunol. 2024 Aug 27;15:1446937. doi: 10.3389/fimmu.2024.1446937. eCollection 2024. Front Immunol. 2024. PMID: 39257589 Free PMC article. Review.
-
Long noncoding RNA: a dazzling dancer in tumor immune microenvironment.J Exp Clin Cancer Res. 2020 Nov 4;39(1):231. doi: 10.1186/s13046-020-01727-3. J Exp Clin Cancer Res. 2020. PMID: 33148302 Free PMC article. Review.
-
Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.Front Immunol. 2021 Jul 6;12:697083. doi: 10.3389/fimmu.2021.697083. eCollection 2021. Front Immunol. 2021. PMID: 34295338 Free PMC article. Review.
-
Long noncoding RNAs in cancer-immunity cycle.J Cell Physiol. 2018 Sep;233(9):6518-6523. doi: 10.1002/jcp.26568. Epub 2018 Mar 25. J Cell Physiol. 2018. PMID: 29574911 Review.
-
Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy.Cells. 2021 Nov 26;10(12):3313. doi: 10.3390/cells10123313. Cells. 2021. PMID: 34943820 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI
-
- Debela DT, Muzazu SG, Heraro KD et al (2021) New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med 9:205031212110343. https://doi.org/10.1177/20503121211034366 - DOI
-
- Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821. https://doi.org/10.1038/s41423-020-0488-6 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources